fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

New data from three oral presentations, showing significant clinical benefit with Sarclisa-based quadruplets in newly diagnosed multiple myeloma patients presented at ASH meeting – Sanofi

Written by | 11 Jan 2025

New data from three oral presentations, which demonstrated significant clinical benefit with Sarclisa-based quadruplets in newly diagnosed multiple myeloma (NDMM) patients were featured at the 66th American Society… read more.

CT scans for lung cancer show potential for detecting elevated coronary artery calcium

Written by | 7 Dec 2024

Lung cancer screening with low-dose chest computed tomography (CT) has the potential to detect coronary artery calcium too, researchers reported on Dec. 2, 2024 in the CMAJ (Canadian Medical Association… read more.

Lung cancer screening CTs find coronary artery disease in 83% of cases

Written by | 3 Dec 2024

Lung cancer screening with low-dose chest computed tomography (CT) may detect more than just lung cancer. As new research in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.231602 shows, these CTs can identify coronary… read more.

Awareness of lung cancer screening remains low

Written by | 10 Nov 2024

There is a lung cancer screening test that is saving lives – and yet most people who could be getting the test have never heard of it or… read more.

Improving medication use – ESCP Day 3 Highlights

Written by | 29 Oct 2024

Therapeutic advances in lung cancer  Molecular testing before the start of treatment is good clinical practice (GCP) and confers considerable benefits in survival, according to Professor Joanna Chorostowska-Wynimko… read more.

Summit Therapeutics announced data from the primary analysis of the Phase III HARMONi-2 trial featuring the novel, potential first-in-class investigational bispecific antibody, ivonescimab

Written by | 16 Sep 2024

Summit Therapeutics Inc. announced data from the primary analysis of the Phase III HARMONi-2 trial featuring the novel, potential first-in-class investigational bispecific antibody, ivonescimab. The data was presented… read more.

A simple test can predict whether smokers will manage to quit

Written by | 19 Aug 2024

Data from nearly 6000 smokers with cancer show that it may be easier to predict who will stop smoking than was previously thought. It is often important to… read more.

FDA advisers call for review of perioperative lung cancer trials – AstraZeneca

Written by | 7 Aug 2024

The FDA’s Oncologic Drugs Advisory Committee (ODAC) has unanimously called for a review of perioperative clinical trial designs in resectable non-small cell lung cancer (NSCLC) to include assessment… read more.

FDA Advisory Committee reviewed Imfinzi (durvalumab) for treatment of resectable non-small cell lung cancer based on AEGEAN Phase III trial results – AstraZeneca

Written by | 3 Aug 2024

The FDA’s Oncologic Drugs Advisory Committee (ODAC) acknowledged that AstraZeneca’s Imfinzi (durvalumab) met the primary endpoints of event-free survival (EFS) in the treatment of resectable non-small cell lung… read more.

Lorbrena (lorlatinib) CROWN study shows majority of patients with ALK-positive advanced lung cancer living beyond five years without disease progression – Pfizer

Written by | 15 Jun 2024

Pfizer Inc. announced longer-term follow-up results from the Phase III CROWN trial evaluating Lorbrena (lorlatinib, a third-generation ALK inhibitor, available in Europe under the brand name Lorviqua) versus… read more.

Tagrisso (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial – AstraZeneca

Written by | 13 Jun 2024

Positive results from the LAURA Phase III trial showed AstraZeneca’s Tagrisso (osimertinib) demonstrated a statistically significant and highly clinically meaningful improvement in progression-free survival (PFS) for patients with… read more.

Study: Access to targeted lung cancer drug is cost-prohibitive globally

Written by | 5 Jun 2024

Many countries with national healthcare systems or payers such as insurance companies use cost-effectiveness analyses to decide whether to cover new medicines, balancing treatment costs with potential health… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.